ImmunoPrecise Antibodies Ltd. (IPA) has announced a collaboration with RIBOPRO to improve the discovery and development of therapeutic antibodies. The partnership will integrate RIBOPRO’s expertise in mRNA sequence optimisation and LNP-based delivery with IPA’s advanced B-cell screening, single-cell analysis, and AI-driven discovery workflows.
Xedev has successfully extended its Good Manufacturing Practice (GMP) authorization to cover the manufacturing and primary packaging of liquid formulations intended for internal use. The expansion broadens the company’s existing approval, which already includes non-sterile and biological medicinal products. With this
Swarm Oncology Ltd. has announced a strategic partnership with Cellex Cell Professionals GmbH, a CDMO specialising in cell and gene therapy manufacturing. The collaboration aims to accelerate the development of Swarm’s novel T cell therapy platform, Swarm-T, which is designed to achieve long-term remission
Kineticos Life Sciences has announced the launch of Kinvard Bio, Inc., a biotech company dedicated to developing new antibiotics to combat antimicrobial resistance (AMR). The company is built on research licensed exclusively from Harvard University’s Myers Lab and is financially supported by Kineticos
Maravai LifeSciences has officially completed its acquisition of Officinae Bio’s DNA and RNA business, expanding its expertise in mRNA design and drug substance manufacturing. The deal integrates Officinae Bio’s AI-enabled mRNA sequence-optimization platform with Maravai and its subsidiary TriLink BioTechnologies‘ manufacturing capabilities, supporting a streamlined
Chime Biologics has reaffirmed its commitment to Mabgeek in advancing MG-K10, a novel IL-4Rα-targeting antibody drug for atopic dermatitis and asthma, into Phase III clinical trials. This collaboration follows Mabgeek’s successful engagement with the U.S. Food and Drug Administration (FDA), paving the way
Granules India Limited has announced the signing of an agreement to acquire Senn Chemicals AG, a Switzerland-based CDMO focused on peptide development and manufacturing. The deal is expected to close in the first half of 2025, subject to regulatory approvals. Senn Chemicals specialises
Psilera, Inc., a biotechnology company focused on neurological disorders, has entered into a licensing agreement with atai Life Sciences, a clinical-stage biopharmaceutical company developing psychedelic-based therapies. Under the agreement, atai has acquired Psilera’s patent portfolio covering DMT and related psychedelics. Psilera’s
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Alvotech have announced the availability of SELARSDI (ustekinumab-aekn) in the United States. This biosimilar to Stelara (ustekinumab) is approved for multiple indications, including psoriatic arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, pediatric plaque psoriasis, and pediatric
Tiziana Life Sciences has signed a product development services agreement with Renaissance Lakewood LLC, a Contract Development and Manufacturing Organization (CDMO) specialising in nasal drug delivery. The partnership aims to refine the formulation of intranasal foralumab and develop a strategy for its large-scale production.
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
